|
Status |
Public on Jul 25, 2018 |
Title |
Foxc1 and Foxc2 are necessary to maintain glomerular podocytes |
Organism |
Mus musculus |
Experiment type |
Expression profiling by array
|
Summary |
Foxc1 and Foxc2 are highly expressed in adult podocytes. To bypass embryonic lethality of Foxc1 and Foxc2 KO, mice ubiquitously expressing inducible-Cre (ROSA26-CreERT2) were mated with floxed-Foxc1 and floxed-Foxc2 mice. We used microarrays to detail effects of deletions of Foxc1 and Foxc2 on podocyte gene expression profiles in adult podocyte in vivo and in vitro.
|
|
|
Overall design |
The CreERT2 was activated in adult mice by administrations of tamoxifen. Isolated glomeruli were subjected to total RNA preparation. Altanatively, primaly cultured podocytes were treated with the active form of tamoxifen and total RNA was prepared on 4 or 7 days after the treatment.
|
|
|
Contributor(s) |
Motojima M |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
|
Submission date |
Jul 24, 2018 |
Last update date |
Aug 05, 2018 |
Contact name |
Masaru Motojima |
Organization name |
Tokai University School of Medicine
|
Department |
Clinical Pharmacology
|
Street address |
143 Shimokasuya
|
City |
Isehara |
State/province |
Kanagawa |
ZIP/Postal code |
259-1193 |
Country |
Japan |
|
|
Platforms (1) |
GPL11202 |
Agilent-026655 Whole Mouse Genome Microarray 4x44K v2 (Probe Name version) |
|
Samples (12)
|
GSM3304018 |
Glomeruli of tamoxufen-treated mouse No.2 |
GSM3304019 |
Podocyte primary culture 4days mock-treated No.1 |
GSM3304020 |
Podocyte primary culture 4days mock-treated No.2 |
GSM3304021 |
Podocyte primary culture 4days tamoxifen-treated No.1 |
GSM3304022 |
Podocyte primary culture 4days tamoxifen-treated No.2 |
GSM3304023 |
Podocyte primary culture 7days mock-treated No.1 |
GSM3304024 |
Podocyte primary culture 7days mock-treated No.2 |
GSM3304025 |
Podocyte primary culture 7days tamoxifen-treated No.1 |
GSM3304026 |
Podocyte primary culture 7days tamoxifen-treated No.2 |
|
Relations |
BioProject |
PRJNA482531 |